Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857002 | 0.91 | SQOR (0.45) | G6PDMAPTKDM4EPTGS2MAPK1 | |
| SCHEMBL4863240 | 0.89 | MAPT (0.50) | G6PDMAPTKDM4EPTGS2MAPK1 | |
| SCHEMBL2947465 | 0.89 | G6PD (0.59) | G6PDMAPTKDM4EPTGS2MAPK1 | |
| SCHEMBL2953222 | 0.88 | MAPT (0.50) | G6PDMAPTKDM4EPTGS2MAPK1 | |
| SCHEMBL14223433 | 0.88 | MAPK1 (0.42) | G6PDMAPTKDM4EPTGS2MAPK1 | |
| SCHEMBL4854567 | 0.88 | KDM4E (0.48) | MAPTKDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL4853398 | 0.88 | KDM4E (0.43) | MAPTKDM4EMAPK1HPGDHSD17B10 | |
| SCHEMBL4855936 | 0.83 | ALDH1A1 (0.48) | MAPTKDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL2951048 | 0.83 | ALDH1A1 (0.48) | MAPTKDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL4857021 | 0.81 | KDM4E (0.48) | MAPTKDM4EHPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | claimed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | claimed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | G6PD 36/4885MAPT 28/4885KDM4E 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.